Kala Pharmaceuticals

194 articles about Kala Pharmaceuticals

• Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

  6/2/2023

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference being held in New York, NY.

• Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/9/2023

  Kala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

  4/28/2023

  Kala Pharmaceuticals, Inc. announced that the California Institute for Regenerative Medicine has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15 million grant to support its ongoing KPI-012 program for the treatment of persistent corneal epithelial defect.

• Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

  4/12/2023

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of persistent corneal epithelial defect (PCED), a rare and debilitating ocular condition.

• Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

  3/29/2023

  Kala Pharmaceuticals, Inc. today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor.

• Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

  3/27/2023

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED).

• Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/8/2023

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference.

• Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/3/2023

  Kala Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

• Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

  12/27/2022

  Kala Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted an investigational new drug application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome, initially in development for the treatment of persistent corneal epithelial defect.

• Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

  11/28/2022

  Kala Pharmaceuticals, Inc. announced that it has entered into a definitive agreement with a life sciences-focused investor for the sale, in a private placement priced at-the-market under Nasdaq rules, of shares of its common stock and Series E Convertible Non-Redeemable Preferred Stock in two tranches for gross proceeds of up to $31 million.

• Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

  11/28/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED).

• Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/8/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

  11/1/2022

  Kala Pharmaceuticals, Inc. today announced the appointment of Marjan Farid, M.D., to its Board of Directors.

• Kala Pharmaceuticals Announces Reverse Stock SplitCommon Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022

  10/20/2022

  Kala Pharmaceuticals, Inc. today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.

• Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference.

• Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Aug 19, 2022

  8/19/2022

  Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635.

• Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

  8/18/2022

  Kala Pharmaceuticals, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022.

• Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/11/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

• Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

  8/8/2022

  Kala Pharmaceuticals, Inc. today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.

• Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August 2022

  8/4/2022

  Kala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, announced that management will participate in the following virtual healthcare investor conferences in August 2022: